5 results about "Atenolol" patented technology

This invention discloses a rapid mass spectrometry method and kit for the simultaneous detection of multiple components in body fluids, belonging to the field of biological detection and identification technology. It can rapidly detect trace compounds such as drugs and biomarkers in complex biological samples. This kit mainly utilizes loaded functional materials to achieve extraction and enrichment of target analytes and is equipped with a quick connector for coupling with a detector to achieve rapid detection. Compared with traditional methods, the significant advantages of the method established by this kit are that it does not require complex sample pretreatment, allows for micro-quantitative sampling, requires small sample volumes, facilitates convenient storage of biological samples, is easy to operate, does not require specialized technical personnel, and enables rapid on-site detection when coupled with portable mass spectrometry. This kit has been successfully used for the detection of quinine, procainamide hydrochloride, atenolol, and nortriptyline in complex samples such as blood and serum, and has significant clinical and economic value.

The application belongs to the technical field of pharmaceutical preparations, and particularly relates to a liposome of atenolol, a preparation method and a preparation. The liposome of atenolol comprises the following components: atenolol, soybean phospholipid, cholesterol, nobiletin and sesbania gum. By optimizing the excipients required in the preparation of the liposome of atenolol, the defects of low drug loading capacity of the liposome of atenolol in the prior art are overcome, the problem of low delivery efficiency of atenolol caused by low drug loading capacity of the liposome of atenolol in the prior art is solved, and the liposome of atenolol is further expanded to be prepared into a preparation. Compared with the prior art, the preparation has higher stability, and the content of related substances is lower than that of a commercial preparation.

The invention discloses a method for simultaneously determining atenolol and a raw material p-hydroxyphenylacetamide thereof based on high performance liquid chromatography, and belongs to the technical field of drug analysis and detection. An instrument adopted by the method disclosed by the invention is Agilent 1260 HPLC (High Performance Liquid Chromatography Octadecylsilane chemically bonded silica is selected as a filling agent for a chromatographic column; a mobile phase is phosphoric acid water and an acetonitrile solution for gradient elution. According to the method, retention of atenolol and the raw material p-hydroxyphenylacetamide on a chromatographic column can be remarkably enhanced, the problem of co-elution caused by similar structural polarities of atenolol and p-hydroxyphenylacetamide is successfully solved, and baseline separation is realized. The method is economical and practical.

The invention belongs to the field of quantitative cell incubation liquid drug concentration analysis, and particularly discloses a method for simultaneously detecting atenolol and digoxin in a cell incubation liquid. According to the method, the concentrations of atenolol and digoxin in the Hanke equilibrium salt buffer solution co-incubated with the cells can be accurately quantified at the same time through specific sample treatment and liquid chromatography and mass spectrometry conditions, the sensitivity is high, the detection limit is low, the normal excretion and transmembrane transport functions of Caco-2 cells in the research process are investigated, and the method has application and popularization value.

The present invention provides compositions comprising a monoamine oxidase inhibitor (MAOI) and a beta receptor blocker (e.g., a beta receptor inhibitor). The invention relates to a dosage form of two of propranolol, metoprolol, carvedilol, timolol, carteolol, atenolol, nebivolol, sotalol, bunenolol, naldalol, seribolol, nebivolol, betalol, esmolol, bisoprolol, oxyprenolol, pentobutolol, labeolol, acebutolol and indolol. And methods of making the dosage forms and using the dosage forms for, for example, the treatment of psychiatric disorders (e.g., depression, major depressive disorder, major depressive disorder associated with anxiety pain, refractory depression, anxiety depression, and mixed anxiety and depression). This abstract is intended as a scanning tool for search purposes in the particular art and is not intended as a limitation on the present invention.